ASX:TLXBiotechs
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Its European Filing For Glioma Imaging Agent TLX101-Px
Telix Pharmaceuticals (ASX:TLX) has lodged a marketing authorization application in Europe for TLX101-Px, an 18F-FET PET imaging agent for glioma. The company is targeting broader access and more consistent diagnostic quality across major markets.
See our latest analysis for Telix Pharmaceuticals.
Telix’s A$8.88 share price comes after a 1-day share price return of 0.45%, but a 30-day share price return decline of 21.28% and a 1-year total shareholder return decline of 66.89%, suggesting...